Beyond animal-first radiotheranostics
Abstract Radiotheranostics has achieved clinical maturity, yet preclinical development remains reliant on animal studies. Direct, dynamic measurement of radionuclide distribution offers a distinctive opportunity to develop quantitative New Approach Methodology (NAM) frameworks. We propose integrating human-relevant models, radionuclide sensing, historical biodistribution data and AI-assisted computational prediction. Fit-for-purpose validation, defined contexts of use and domains of applicability, and quantified predictive uncertainty could support reliable translational decisions and enable development beyond animal-first pipelines.
Authors
- Jordi Llop (ORCID: https://orcid.org/0000-0002-0821-9838)
- Claudia Esposito-Zapero (ORCID: https://orcid.org/0000-0003-2287-7842)
- Marco Cavaco (ORCID: https://orcid.org/0000-0002-0938-9038)
- Margarida M. Domingos
- Christopher J. Mann
- Ella-May Hards
Institutions
- University of Lisbon (PT)
- CIC biomaGUNE (ES)
- Instituto Gulbenkian de Ciência (PT)
Publication Details
- Journal
- npj Imaging
- Published
- 2026-11-14
- DOI
- https://doi.org/10.1038/s44303-026-00218-y
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00